top of page

Ozempic (semaglutide) - #PHARMFAX

There is an Ozempic (semaglutide) shortage and patients with T2DM can’t even get it.

 

There is an Ozempic (semaglutide) shortage and patients with T2DM can’t even get it. Semaglutide is prescribed as an adjunctive therapy for T2DM. It acts as a glucagon-like peptide 1 receptor agonist, which stimulates insulin release from functioning beta cells on the pancreas and delays gastric emptying. There has been a recent shortage given an increase in off-prescribing for its role in weight loss for non-diabetics. Let’s make sure you’re informed. The common side effects include admoinal pain and diarrhea. In rare cases, patients may develop pancreatitis or diabetic retinopathy complications. Per the package insert, its stated the semaglutide had a dose-dependent and treatment-duration-dependent incidence of tumors in tested rates, and that the effect on humans is unknown. Thats a no for me pham if I don’t have a history of diabetes. Hungry for more PHARMFAX, check out the other videos on my page. #medicine #pharmacy #pharmwyze #ozempic #semaglutide Visit my website www.pharmwyze.com References can also be found here Follow @pharmwyze on your favorite social media platform. Not medical advice. Educational purposes only. No relationships to report. I hope you learned something new.

3 views0 comments

Comments


bottom of page